Klor-Con

(Potassium chloride)

ApprovedSmall molecule

Potassium chloride is used to treat or prevent low potassium levels in the blood, which can cause muscle weakness, irregular heartbeat, and other health problems.[2] Klor-Con is currently approved and in use across 18 indications[4].[1]

Klor-Con is one of 390 small molecule programs targeting Constipation. It is currently in Approved.

Indications

Total Trials

Active Trials

389

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

Cardiac ArrhythmiaActive, not recruiting

Cardiac ArrestActive, not recruiting

HypokalemiaActive, not recruiting

HemorrhageActive, not recruiting

Aortic StenosisActive, not recruiting

Diastolic Heart FailureApproved

Metabolic AcidosisActive, not recruiting

HypertensionApproved

Brain NeoplasmApproved

Septic ShockApproved

Cardiac ArrhythmiaApproved

Active, not recruiting

Cardiac ArrestPhase 2

Active, not recruiting

HypokalemiaApproved

Active, not recruiting

HemorrhageApproved

Active, not recruiting

Aortic StenosisPhase 2

Active, not recruiting

Diastolic Heart FailureApproved

Approved

Metabolic AcidosisPhase 2

Active, not recruiting

HypertensionApproved

Approved

Brain NeoplasmApproved

Approved

Septic ShockApproved

Approved

Showing 10 of 17 indications

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Klor-Con

Novartis

Approved

3 2

Savaysa

Activase

Zemplar

Xifaxan

2 6

Tamiflu

CConrado Roberto Hoffmann Filho

Preclinical

1 7

Oraverse

LLife Extension Foundation Inc.

Preclinical

1 8

Coumadin

AAbbott

Preclinical

1 9

Neo-Synephrine

EExela Pharma Sciences, LLC.

Statin

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Phase 2/3Not yet recruiting

Heart Failure

NCT07469722

Q1 2029

Phase 2Recruiting

Hypertension

NCT07238400

Clinical

Trials by Indication[1]

Hypertension5 trials

Prevention of Severe Postpartum Hypertension

Withdrawn·IIndiana University·Phase 2·NCT02450773

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

Completed·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT01682837·35 enrolled

Value of Liquid Potassium Magnesium Citrate in Controlling Hypertension

Completed·UUniversity of Texas Southwestern Medical Center·Phase 4·NCT02653560·30 enrolled

Show 2 more trials

Uric Acid and Hypertension in African Americans

Completed·UUniversity of Florida·Phase 3·NCT00241839·150 enrolled

Cardiac Effects of Mineralocorticoid Receptor Antagonism After Preeclampsia

Recruiting·MMassachusetts General Hospital·Phase 2·NCT07238400·90 enrolled

Heart Failure3 trials

Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure

Completed·—··NCT06233695·100 enrolled

Effect of KNO3 Compared to KCl on Oxygen UpTake in Heart Failure With Preserved Ejection Fraction (KNO3CK OUT HFPEF)

Completed·UUniversity of Pennsylvania·Phase 2·NCT02840799·84 enrolled

POcus INTERvention for Tailoring Diuretic Strategy in Acute Decompensated Heart Failure

Not yet recruiting·HHospital de Clinicas de Porto Alegre·Phase 2/3·NCT07469722·128 enrolled

Cardiac Arrest1 trial

Potassium Chloride in Out-of-hospital Cardiac Arrest Due to Refractory Ventricular Fibrillation

Withdrawn·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT04316611

Aortic Stenosis1 trial

Targeting Pulsatile Load to Increase Exercise Capacity and Quality of Life After Aortic Valve Replacement for Severe Aortic Stenosis (PULSE AS)

Completed·UUniversity of Pennsylvania·Phase 2·NCT03483051·5 enrolled

Hypoparathyroidism1 trial

Recombinant Human rhPTH(1-34) VS Association Alfacalcidol/Hydrochlorothiazide in Severe Primary Hypoparathyroidism

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT02824718·16 enrolled

10 more indications

Atrial Fibrillation1 trial

Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter

Completed·—·Phase 4·NCT01818583·143 enrolled

Pregnancy1 trial

Prenatal Screening, Diagnosis and Intrauterine Intervention of Fetal Abnormal Chromosome and Structure in Twins Pregnancy

Unknown status·SShanghai First Maternity and Infant Hospital·N/A·NCT02982356·1,300 enrolled

High Risk1 trial

Pre-ESRD Syndrome in High Risk African Americans

Terminated·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·N/A·NCT00224939·144 enrolled

Intravenous1 trial

Comparison of Enteral Versus Intravenous Potassium Supplementation

Unknown status·—·Phase 4·NCT02015962·40 enrolled

Metabolic Acidosis1 trial

Metabolic Acidosis in Renal Transplant Patients

Completed·UUniversity of Zurich·Phase 2·NCT00913796·30 enrolled

Cognitive Functions1 trial

The Impact of Air Travel on Passenger Cognitive Functions

Unknown status·DDinara Zhumanbayeva·Phase 2/3·NCT04802785·50 enrolled

Side Effects1 trial

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

Completed·UUniversity of Texas Southwestern Medical Center·N/A·NCT02665117·61 enrolled

Nephropathy1 trial

The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy

Completed·BBarts & The London NHS Trust·Phase 2·NCT03627130·640 enrolled

Intensive Care1 trial

Comparison of Two Potassium Targets Within the Normal Range in Intensive Care Patients

Completed·UUniversity Medical Center Groningen·Phase 4·NCT01085071·1,225 enrolled

Blood Pressure1 trial

Potassium-Magnesium Citrate as a Blood Pressure Lowering Agent in Hypertensive Patients

Withdrawn·UUniversity of Texas Southwestern Medical Center·Phase 1/2·NCT01074918

Regulatory

FDA Approval Timeline[5]

Jan 1, 1982

KAON CL

NDA NDA017046

Jan 1, 1982

KLOTRIX

NDA NDA017850

Jan 1, 1982

POTASSIUM CHLORIDE

NDA NDA007865

Jan 1, 1982

SLOW-K

NDA NDA017476

Jan 1, 1982

MICRO-K

NDA NDA018238

Apr 16, 1986

TEN-K

NDA NDA019381

Apr 17, 1986

KLOR-CON

NDA NDA019123

Jun 13, 1986

POTASSIUM CHLORIDE

NDA NDA019439

Aug 1, 1988

K-TAB

NDA NDA018279

Aug 26, 1988

MICRO-K LS

NDA NDA019561

Dec 26, 1989

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

NDA NDA019904

Nov 30, 1992

POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER

NDA NDA020161

Aug 25, 2023

POKONZA

NDA NDA208019

Nov 25, 2025

POKONZA

NDA NDA206814

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Potassium chloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Klor-Con drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Potassium chloride compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Potassium chloride. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA206814). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Klor-Con. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Novartis company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Novartis

Patent Landscape[6]

Patent Cliff

Mar 7, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12539314Mar 7, 2039

Klor-Con

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q1 2029

Trials by Indication[1]

Hypertension5 trials

Heart Failure3 trials

Cardiac Arrest1 trial

Aortic Stenosis1 trial

Hypoparathyroidism1 trial

Atrial Fibrillation1 trial

Pregnancy1 trial

High Risk1 trial

Intravenous1 trial

Metabolic Acidosis1 trial

Cognitive Functions1 trial

Side Effects1 trial

Nephropathy1 trial

Intensive Care1 trial

Blood Pressure1 trial

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News